This is a different post in that I am going to be focusing on proprietary data and analysis. Below is summary of the findings and then I will talk more generally about the data. This should be of value and if there are particular ways in which you would like to see the data or […]
March 20th Biotech Update
The biotech and pharma sector is moving in a more constructive direction in 2026, but it is a selective recovery rather than a broad risk-on melt-up. The backdrop is improving because investors are rewarding companies with mature pipelines, credible late-stage data, and realistic paths to commercialization, while M&A appetite has picked up after a long […]
February 11th Biotech Update
The still dominated by the metabolic franchise, with GLP-1s representing one of the largest value creation cycles in sector history. One has to think that the fate of this market plays a large part of generalist interest going forward. Shares of NOVO and LLY have been highly sensitive to competitive dynamics, supply constraints, and incremental […]
January 23rd Biotech Update
The sector continues to plod along. I think there is some interesting news with the oral GLP launch and while it certainly has import for the companies involved, I think the sector does best when there is a big launch that creates buzz outside the sector. It is the generalists that really push bull markets […]
October 14th Biotech Update
Over the past few days, biotech and pharmaceutical stocks have seen mixed but generally positive moves sparked by deal news and strong individual performers. This environment reinforces the more positive sentiment around the sector but with a preference now being placed on pipelines with strong differentiation, regulatory path clarity, or acquisition potential. It seems the […]
June 18th Biotech Update
I feel worried saying this but the sector is doing well at least when one looks at the chart. This certainly does not mean that the headwinds and concerns are suddenly going away but bull markets are built on climbing a wall of worries and there are a lot of worries that could be climbed […]
April 5th Biotech Update
So, we are at the area where we have bounced off of what might be a major bottom and have basically closed a gap to the upside. The market is overbought and that is likely the case for the sector as well. All of this being said, it seem like a natural place for a […]
February 21st Biotech Update
Did we have a clearing event with the confirmation of RFK JR or is that copium? The initial indication is that there has been a little relief rally and if we can keep as close to the old status quo as possible (not too many massive changes) and rates can come down then the sector […]
February 11th Biotech Update
Still not looking great for the sector. While there is not a ton of positive news to move the sector forward, rates are starting to tick higher. Perhaps this is only a momentary move, and we will reverse lower on rates but if rates start a more consistent move higher, then there is no shot […]
January 24th Biotech Update
Well, the sector is doing a little better but we are still not out of the woods. I would feel better once we break out of the recent high. We do not want to be in a situation where we set a lower high. We are close but need to get above $95 before we […]
January 22nd Biotech Update
So the sector is looking a little better. I would not say it looks good but a nice little move the other day takes it away from the abyss. That being said there still is the possibility that we are going to set a lower high followed by a lower low. We need to get […]
January 6th Biotech Update
We are now making our way out of holiday trading and into what I would say is the first real trading day of the new year. I still think the sector trading will be focused on the upcoming JPM meeting next week and so whatever happens this week can change dramatically next. The key is […]
November 26th Biotech Update
A nice recovery for the sector and so it is not surprising that we see a little pause. Perhaps we can continue the momentum the rest of the week but we are approaching a holiday and so I expect volumes to slow down and the momentum of this initial bounce to pause. This is not […]
October 30th Biotech Update
Not much to say about the sector as we continue in the range and are a little higher today as we move towards the upper end of the range. Of course, it is always nicer to be near the higher end than the lower end but as always the expectation should always be that we […]
July 31st Biotech Update
I am in the middle of moving cross country and so will be hit and miss for the next month or so. I am back for a little bit but also have to catch up on earnings and news. I will try and take it in bits and pieces as opposed to doing it all […]
July 8th Biotech Update
It is going to be an interesting week. We have been pretty slow on the news front and last week was a holiday week with the expected dry up in volume. I get that it is still summer, and trading is going to remain slow but coming off of a holiday we get some interesting […]
May 31st Biotech Update
Nothing really to add on the sector or market in general. It is all about inflation and rates and will be so for the foreseeable future. The sector has been struggling a little and I think probably a little more than I would have originally expected. I understand that rates are heading up a little […]
May 22nd Biotech Update
We are hanging out. I do feel like there is a little more interest in the sector than has been and obviously it is related to rates. They have trended down recently, and the talk is that CPI should be cooling off as well. The FED has not really changed its tone a lot and […]
May 17th Biotech Update
It has been a pretty good week for the sector with a nice steady move higher. It has not be an absolute straight line nor has it been dramatic one but a slow build higher is not too bad. In some ways, this is better than an accelerating move as this provides more volume at […]
May 1st Biotech Update
I would not say that we got momentum but trading in line with the market (if not a little better in parts) is not the worst scenario. I will continue to be a broken record with my call on rates and that once they stabilize they sector will finally start to trade more on fundamentals […]
